GASTRIC ADENOCARCINOMA

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

This Phase 3 trial is testing whether a new targeted drug called sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly an immunotherapy (rilvegostomig), can help people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specifi…

This large Phase 3 trial is testing whether a newer targeted drug, trastuzumab deruxtecan (Enhertu), combined with chemotherapy and possibly the immunotherapy pembrolizumab (Keytruda), works better than the current standard treatment for advanced HER2-positive stomach or gastroes…

This study tests a new drug called DR30206 combined with standard treatments for people with advanced or spreading gastrointestinal cancers, like colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. About 186 adults in China will take part.

This Phase 3 trial tests a new drug called JS107 combined with toripalimab and chemotherapy against a standard treatment for advanced stomach cancer that has a specific marker (CLDN18.2). The study plans to enroll 600 people whose cancer has spread and cannot be removed by surger…

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This phase 2 trial tests whether adding an experimental biologic called TRK-950 to the standard combination of ramucirumab and paclitaxel helps people with advanced stomach or gastroesophageal junction cancer. Participants receive either the standard two-drug regimen or the stand…

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This phase 2 trial is testing a combination of three chemotherapy drugs plus immunotherapy as a first treatment for advanced esophageal and gastric cancer. For patients with HER2-positive tumors, the targeted drug trastuzumab is also added. The study aims to see if this mix is mo…

This Phase 3 trial is testing whether a new drug combination (tecotabart vedotin plus tislelizumab) works better than standard chemotherapy for people with advanced stomach cancer that has a specific protein called CLDN18.2. The study plans to enroll 752 participants who have not…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This study tests whether giving the chemotherapy drug paclitaxel directly into the abdominal cavity, along with standard intravenous chemo, can help people with stomach cancer that has spread to the lining of the abdomen. About 148 adults with this condition will be randomly assi…

This study tests several new drug combinations given before and after surgery for stomach or esophageal cancer. About 100 people with resectable tumors will receive these treatments to see if they are safe and can shrink or eliminate the cancer. The goal is to improve outcomes by…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This early-phase trial tests a new drug called ASP2138, which helps the immune system attack cancer cells that have a specific marker (CLDN18.2). It is for people with advanced stomach, gastroesophageal junction (GEJ), or pancreatic cancer that cannot be removed by surgery or has…

This study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…

This early-stage trial is testing an experimental drug called CHS-114 combined with the immunotherapy toripalimab, with or without standard chemotherapy, in 154 people with advanced or metastatic solid tumors. The main goal is to see if the combination is safe and to get an early…

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

This study tests a new experimental drug, PF-08634404, combined with chemotherapy in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new…

This study tests whether adding the supplement taurine to a standard treatment (immunotherapy drug serplulimab plus chemotherapy) can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 96 adults whose tumors have a specific marker…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…

This early-stage trial is testing a new treatment called DISP-10 for people with advanced gastrointestinal cancers, including colorectal and stomach cancers. The treatment combines a virus (DV-10) with specially engineered immune cells (CAR T cells) to attack cancer. The study ai…

This study is testing a new way to give radiation therapy (called PULSAR) along with standard chemotherapy and immunotherapy for people with advanced stomach cancer that cannot be removed with surgery. The radiation is given in high doses every few weeks, tailored to each patient…

This phase 2 study is testing whether adding two newer drugs—pembrolizumab (an immunotherapy) and trastuzumab (a targeted therapy)—to standard chemotherapy can help people with HER2-positive esophageal or stomach cancer that can be surgically removed. About 49 adults will receive…

This study tests new experimental drugs combined with standard chemotherapy and immunotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery or has spread. About 160 participants will receive the combination to …

This study tests whether the chemotherapy drug paclitaxel, given before and after stomach removal surgery, can improve outcomes for people with gastric cancer that has spread to the lining of the abdomen. About 30 adults with this condition will receive the drug and be monitored …

This Phase 2 trial is testing a new drug called denikitug, alone or combined with other cancer drugs, in 120 people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. The main goal is to see if the drug …

This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…

This study tests an experimental drug called LBL-024 combined with other cancer drugs (capecitabine, tislelizumab, and oxaliplatin) in 110 adults with advanced solid tumors. The goal is to see if the combination shrinks tumors and is safe. Participants must be in good overall hea…

This study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus chemotherapy, or a stand…

This clinical trial is looking at the best timing for local treatments like surgery or radiation in people with esophageal or stomach cancer that has spread to only a few spots. All participants first get 4 months of standard drug therapy. Then, depending on their response, they …

This phase 2 trial is testing whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706) plus standard chemotherapy can help people with advanced HER2-negative stomach cancer that has low PD-L1 levels. The study will enroll 77 particip…

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This Phase II trial is testing a two-step treatment for stomach cancer that has spread to the lining of the abdomen. First, patients receive chemotherapy and a minimally invasive heated chemo wash. Then, they undergo major surgery to remove visible tumors, followed by another rou…

This phase II trial tests whether adding surgery and radiation to standard chemotherapy can improve outcomes for people with stomach cancer that has spread only to nearby lymph nodes. About 54 participants will receive either standard chemo or a more intensive plan including chem…

This early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…

This study tests a combination of drugs (LM-302, S-1, and intraperitoneal paclitaxel) with or without another drug (cadonilimab) in people with a specific type of advanced stomach cancer (Claudin 18.2-positive) that has spread to the lining of the abdomen. The goal is to see if t…

This phase 2 study tests a new approach for people with advanced stomach, esophageal, or gastroesophageal junction cancer that is either PD-L1-negative or has stopped responding to immunotherapy. Participants receive injections of a cancer-killing virus (OBP-301) directly into th…

This phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 61 participants will receive the drug combination before and after sur…

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from returning. About 70 adults who have had their tumor removed will receive the combination treatment …

This study is for people with esophageal or stomach cancer that has spread to 3 or fewer places in the body. It compares standard chemotherapy alone to chemotherapy plus radiation or surgery to the main tumor and those spots. The goal is to see if adding local treatment helps peo…

This study tests a new drug called ATG-022 combined with the immunotherapy pembrolizumab (Keytruda), with or without chemotherapy, in people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and is HER2-negative. The trial aims to fin…

This study tests a new way to treat stomach cancer that has spread to the lining of the belly. Doctors will use a robot to remove visible cancer and then deliver heated chemotherapy directly into the abdomen during surgery. The goal is to help patients recover faster and have few…

This study tests a combination of three chemotherapy drugs (docetaxel, oxaliplatin, and S-1) given before surgery to people with advanced stomach cancer that cannot be removed right away. The goal is to shrink the tumor enough so that surgery can remove it completely. About 63 ad…

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) can help prevent stomach or gastroesophageal junction cancer from coming back after surgery. It includes 276 adults with high-risk or specific genetic types of cancer. Participants ar…

This study tests whether adding an immune-boosting drug (thymalfasin) to standard chemotherapy and immunotherapy can help shrink stage III stomach or gastroesophageal junction cancer before surgery. About 30 adults aged 18-75 will receive the combination, then have their tumor ti…

This study tests an experimental drug called AZD5863 in adults with advanced stomach, gastro-esophageal junction, pancreatic, or esophageal cancers that have spread. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to attack them. The main go…

This study is testing a drug called zolbetuximab combined with standard chemotherapy in people with a specific type of advanced stomach cancer that has spread. The cancer must have a protein called claudin 18.2 on at least 75% of its cells and be HER2-negative. The goal is to see…

This phase 3 trial is testing whether a new combination of drugs (SHR-A1811, adebrelimab, and chemotherapy) works better than the current standard treatment for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The study will enrol…

This study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…

This study tests whether adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery helps people with stomach or gastroesophageal junction cancer that can be removed. About 760 participants will receive either cadonilimab plus chemo or a placebo plus chem…

This study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…

This study looks at different drug combinations for people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. Researchers will observe 250 participants receiving albumin-bound paclitaxel-based regimens, including immune check…

This early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally…

This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, rectal, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This study tests whether combining the targeted drug cabozantinib with immunotherapy drugs (durvalumab, with or without tremelimumab) is safe and effective for people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that c…

This study looks at whether giving heated chemotherapy directly into the abdomen during surgery can help prevent stomach cancer from coming back. About 200 adults with advanced stomach cancer that has spread to the lining of the abdomen will receive the treatment. The goal is to …

This study tests a combination of three drugs (fruquintinib, trastuzumab, and chemotherapy) as a first treatment for people with HER2-positive advanced stomach or gastroesophageal junction cancer. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth…

This Phase 2 study is testing several new drug combinations for people with stomach or gastroesophageal junction cancer who have not had prior treatment. The combinations include an immunotherapy drug (adebrelimab) plus targeted drugs (SHR-A1811, SHR-A1904, or SHR-8068) and chemo…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This study tests a combination of three drugs (SHR-1701, rivoceranib, and possibly SHR-2554) in 40 adults with advanced stomach or gastroesophageal junction cancer that worsened after or could not tolerate first-line immunotherapy. The goal is to see if the new combo can shrink t…

This study tests whether taking glutamine by mouth can help gastric cancer patients regain muscle and improve nutrition after having their stomach removed. About 120 adults who had stomach cancer surgery will take glutamine supplements and be monitored for changes in muscle size,…

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or gastroesophageal junction cancer that can be removed. The goal is to see if this longer pre-surgery…

This early-stage study tests whether combining two drugs (sacituzumab govitecan and capecitabine) is safe for people with advanced gastrointestinal cancers that have stopped responding to standard treatments. About 20 adults with stomach, colorectal, or pancreatic cancer will tak…

This study tests a new drug called TST001, an antibody that targets a protein called Claudin18.2 found on some cancer cells. It is given alone or with chemotherapy to people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check s…

This study looks at whether it's safe to avoid placing drainage tubes in the belly after laparoscopic surgery for stomach cancer. About 454 adults with early to advanced stomach cancer will be randomly assigned to get either the standard recovery plan with drains or a streamlined…

This phase 2 trial is testing whether the immunotherapy drug dostarlimab can work better than standard chemotherapy as a first treatment for people with rare, advanced cancers that have a specific genetic flaw called dMMR/MSI. The study includes 120 adults with cancers like pancr…

This study looks at whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (SOX) can help prevent stomach cancer from coming back after surgery. It involves 460 adults with a specific type of advanced stomach cancer (PD-L1 positive, stage N3). Participants are…

This study tests a new chemotherapy drug called utidelone, given as a capsule, together with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The trial will enroll about 778 participants across multiple c…

This phase 3 trial tests a new drug called BL-M07D1 against standard chemotherapy in 490 people with HER2-positive advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. The study aims to see if BL-M07D1 helps people live longer or slows c…

This study tests a new drug called Spevatamig (PT886) in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The drug is a type of antibody that targets two proteins on cancer cells to help the immune system attack them…

This phase 3 trial tests a new treatment called IMC002, which uses a patient's own immune cells (CAR T-cells) engineered to target a protein called CLDN18.2 found on some stomach cancer cells. The study includes 150 adults with advanced stomach cancer that has not responded to at…

This study tests whether adding tadalafil (a drug used for erectile dysfunction) to standard chemotherapy can help shrink stomach or gastroesophageal junction tumors before surgery. Ten adults with resectable cancer will receive tadalafil alone for two weeks, then combined with c…

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

This study tests whether a combination of three drugs (RC48, sintilimab, and SOX) can shrink advanced stomach cancer enough to allow surgical removal. It includes 30 adults with a specific type of HER2-positive cancer who have not had prior treatment. The goal is to see how many …

This early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard…

This study compares two surgical approaches for stomach cancer: removing the entire omentum (a fatty layer in the abdomen) versus preserving it. The omentum helps fight infections and prevent bowel blockages. Researchers want to see if keeping it leads to fewer complications with…

This study is testing an artificial intelligence tool called DeepComp that uses CT scans and patient data to predict which stomach cancer patients are at high risk for major complications after surgery. Researchers will enroll 500 patients across five medical centers and compare …

This study is testing a new, non-invasive stool test that looks for specific gene changes in H. pylori bacteria linked to stomach cancer. Researchers will compare the test's accuracy with a standard risk questionnaire in 15,000 adults aged 40 and older. The goal is to see if this…

This study looks at whether a small tissue sample taken during an endoscopy (biopsy) can give the same information about gastric cancer as a larger sample taken during surgery. Researchers will compare results from 510 patients to see if the biopsy is just as accurate for key can…

This study compares two common surgical techniques used to reconnect the digestive tract after partial stomach removal for gastric cancer: Billroth II (one connection) and Roux-en-Y (two connections). The goal is to see which method leads to better quality of life one year after …

This study tests a software tool called myDIET that helps manage nutrition in people with stomach or esophageal junction cancer who are scheduled for surgery. Patients answer simple questions about eating, weight, and symptoms, and the tool gives tailored advice. The goal is to s…

This study compares symptoms, especially appetite, in patients who have one of two types of minimally invasive stomach cancer surgery: removing only the upper part of the stomach or the whole stomach. Researchers will track how patients feel using a simple questionnaire. The goal…

This study is testing whether a personalized blood test that looks for tumor DNA can detect stomach cancer recurrence earlier than standard imaging. About 110 patients who had chemotherapy and surgery for stage II-III stomach cancer will give blood samples over time. The goal is …

This study looks at whether a blood test that detects tumor DNA (ctDNA) can help doctors monitor how well treatment is working in people with stomach cancer. About 600 participants will provide blood samples before and during treatment to see if changes in ctDNA levels predict re…

This study is looking at 400 people with stomach cancer who had surgery to remove the tumor and nearby lymph nodes. Researchers want to see if the number of lymph node areas that contain cancer can help predict how long patients will live. The goal is to better understand which p…

This study looks at tissue samples from 30 adults with stomach or esophageal cancer that spread to the brain. Researchers compare the genetic markers of the original tumor and the brain tumor to see if they differ. The goal is to better understand how these cancers change when th…

This study is building a registry of 3,200 people with early changes in the stomach lining that can lead to gastric cancer. Researchers will collect information on lifestyle, diet, and other risk factors through questionnaires. The goal is to better understand why some people dev…

This study is a large registry that will collect information from about 1,900 people with advanced cancer of the esophagus or stomach who are receiving palliative treatment in Germany. The goal is to understand what treatments are actually used in everyday practice and how patien…

This study is testing a new blood test to find tiny traces of stomach cancer that might be left behind after surgery. The goal is to catch a recurrence earlier than standard scans. Researchers will collect blood samples from 500 people who had their stomach cancer removed and fol…

This study looks at where tumor deposits form after gastric cancer surgery. Researchers will examine tissue from 100 patients who had a specific type of stomach removal. The goal is to learn more about how cancer spreads in the abdomen, which may guide future treatments.

This study is observing 150 people with stomach cancer who are having surgery to remove the stomach and nearby lymph nodes. The goal is to see how often cancer spreads to a specific group of lymph nodes near the stomach. The findings could help doctors decide exactly which lymph …

This study observes 200 people with stomach cancer who are having a specific type of surgery called distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision. The goal is to check how often cancer has spread to lymph nodes and tumor deposits in the back stomac…